Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients.
Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, Vandamme T, Serdons K, Koole M, Bormans G, Laenen A, Clement PM, Geboes K, Van Cutsem E, Nackaerts K, Stroobants S, Verslype C, Van Laere K, Deroose CM.
Boeckxstaens L, et al.
EJNMMI Res. 2023 Jun 1;13(1):53. doi: 10.1186/s13550-023-01003-3.
EJNMMI Res. 2023.
PMID: 37261615
Free PMC article.
METHODS: Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [(68)Ga]Ga-DOTATATE PET/CT, performed within 3 months, were prospectively included. ...RESULTS: In total, 195 unique lesions were detected: 167 with [(68)Ga …
METHODS: Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [(68)Ga]Ga-DOTATATE PE …